Comparison of Intravitreal Bevacizumab and Triamcinolone with Placebo in Acute Nonarteritic Anterior Ischemic Optic Neuropathy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT1138901221180N13

Enrollment

Registered

2010-05-21

Start date

2009-11-14

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anterior Ischemic of Optic Nerve. Disorders of optic nerve, not elsewhere classified

Interventions

Intervention 1: Control: placebo. Intervention 2: Intervention: Avastin 1.25 mg and Triamcinolone 2 mg one time.

Placebo

Treatment - Drugs

Control: placebo

Intervention: Avastin 1.25 mg and Triamcinolone 2 mg one time

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: sudden mono ocular vision loss associated with optic disc edema and positive Marcus Gunn (<30 days). Exclusion criteria: any eye disease except NAION (Nonarteritic Anterior Ischemic Optic Neuropathy), neurologic defect, abnormal ESR, CRP, any history of retina or vitrea surgery, severe corneal opacity which makes retina examination impossible.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
BCVA. Timepoint: 1,3, 6 months. Method of measurement: snellen chart.	—

Secondary

Measure	Time frame
Visual field. Timepoint: 1,3,6 months. Method of measurement: snellen.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mohammad Pakravan

Ophthalmic Rsearch Center, Shahid Beheshti University of Medical Sciences

labbafi@hotmail.com+98 21 2259 2200

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026